Celcuity Inc.
General ticker "CELC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.2B (TTM average)
Celcuity Inc. follows the US Stock Market performance with the rate: 41.0%.
Estimated limits based on current volatility of 4.5%: low 85.32$, high 93.31$
Factors to consider:
- Total employees count: 155 (+78.2%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Inability to achieve profitability, Capital raising failure, Clinical trial failure, Regulatory and compliance
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [33.69$, 87.07$]
- 2026-12-31 to 2027-12-31 estimated range: [21.00$, 56.37$]
Financial Metrics affecting the CELC estimates:
- Negative: with PPE of -26.6 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -1.21 <= -0.60
- Negative: 0.01 < Interest expense per share per price, % of 0.32
- Negative: -0.75 < Inventory ratio change, % of 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CELC quotes
Long-term CELC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $66.23MM | $113.27MM | $172.19MM |
| Operating Income | $-66.23MM | $-113.27MM | $-172.19MM |
| Non-Operating Income | $2.45MM | $1.49MM | $-4.85MM |
| Interest Expense | $5.33MM | $10.28MM | $17.15MM |
| R&D Expense | $60.59MM | $104.20MM | $145.00MM |
| Income(Loss) | $-63.78MM | $-111.78MM | $-177.04MM |
| Net Income(Loss)* | $-63.78MM | $-111.78MM | $-177.04MM |
| Stockholders Equity | $139.77MM | $115.62MM | $100.56MM |
| Assets | $191.22MM | $245.12MM | $466.56MM |
| Operating Cash Flow | $-53.81MM | $-83.47MM | $-153.28MM |
| Capital expenditure | $0.10MM | $0.25MM | $0.25MM |
| Investing Cash Flow | $-5.01MM | $-63.07MM | $-64.08MM |
| Financing Cash Flow | $64.91MM | $138.39MM | $360.55MM |
| Earnings Per Share** | $-2.69 | $-2.83 | $-3.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.